Assessing a Suitable Radiotherapy Utilisation Benchmark for Older Patients With Head and Neck Cancer

IF 3.2 3区 医学 Q2 ONCOLOGY Clinical oncology Pub Date : 2024-05-31 DOI:10.1016/j.clon.2024.05.014
{"title":"Assessing a Suitable Radiotherapy Utilisation Benchmark for Older Patients With Head and Neck Cancer","authors":"","doi":"10.1016/j.clon.2024.05.014","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><p>To (i) determine the actual radiotherapy utilization (RTU) stratified by age, (ii) develop an age- and co-morbidity adjusted optimal RTU model and (iii) examine the tolerance and toxicity of treatment of older patients with head and neck cancer.</p></div><div><h3>Materials and methods</h3><p>A retrospective cohort study based on New South Wales Cancer Registry records (2010–2014) linked to radiotherapy data (2010–2015) and admitted patient data (2008–2015) for patients diagnosed with head and neck cancer. We calculated the actual RTU, defined as the proportion of patients who received at least one course of radiotherapy within a year of diagnosis, by age group, including patients aged 80+ years. We also calculated the age and comorbidity-adjusted optimal RTU. For treatment tolerance, the radiotherapy dose for each age group and the completion rate for a seven week 70 Gray (Gy) course of curative intent radiotherapy were computed. The number of emergency department (ED) presentations were used as a surrogate measure of acute treatment toxicity for patients receiving 70 Gy.</p></div><div><h3>Results</h3><p>Of the 5966 patients diagnosed with head and neck cancer, 814 (13.6%) were aged 80+ years. For all age groups, the actual RTU was less than the optimal RTU. The age- and comorbidity-adjusted optimal RTU for patients aged 80+ was 52% (95% CI: 51%–53%), and the actual RTU was 40% (95% CI: 37%–44%). Only 4.4% of patients aged 80+ received 70 Gy, and the completion rate for a 70 Gy course of radiotherapy for these patients was 92%. The ED presentation rate was similar for all age groups.</p></div><div><h3>Conclusion</h3><p>The actual RTU was less in the 80+ years patients and across all age groups. Fewer patients in the 80+ group received curative intent schedules compared to the actual RTU rate for younger age groups, despite similar rates of completion of curative intent radiotherapy and acute toxicity.</p></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0936655524002097/pdfft?md5=82e526f012c2de7a0249944d624a1803&pid=1-s2.0-S0936655524002097-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0936655524002097","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aims

To (i) determine the actual radiotherapy utilization (RTU) stratified by age, (ii) develop an age- and co-morbidity adjusted optimal RTU model and (iii) examine the tolerance and toxicity of treatment of older patients with head and neck cancer.

Materials and methods

A retrospective cohort study based on New South Wales Cancer Registry records (2010–2014) linked to radiotherapy data (2010–2015) and admitted patient data (2008–2015) for patients diagnosed with head and neck cancer. We calculated the actual RTU, defined as the proportion of patients who received at least one course of radiotherapy within a year of diagnosis, by age group, including patients aged 80+ years. We also calculated the age and comorbidity-adjusted optimal RTU. For treatment tolerance, the radiotherapy dose for each age group and the completion rate for a seven week 70 Gray (Gy) course of curative intent radiotherapy were computed. The number of emergency department (ED) presentations were used as a surrogate measure of acute treatment toxicity for patients receiving 70 Gy.

Results

Of the 5966 patients diagnosed with head and neck cancer, 814 (13.6%) were aged 80+ years. For all age groups, the actual RTU was less than the optimal RTU. The age- and comorbidity-adjusted optimal RTU for patients aged 80+ was 52% (95% CI: 51%–53%), and the actual RTU was 40% (95% CI: 37%–44%). Only 4.4% of patients aged 80+ received 70 Gy, and the completion rate for a 70 Gy course of radiotherapy for these patients was 92%. The ED presentation rate was similar for all age groups.

Conclusion

The actual RTU was less in the 80+ years patients and across all age groups. Fewer patients in the 80+ group received curative intent schedules compared to the actual RTU rate for younger age groups, despite similar rates of completion of curative intent radiotherapy and acute toxicity.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
为老年头颈癌患者评估合适的放疗利用率基准。
目的:(i) 确定按年龄分层的实际放射治疗利用率(RTU);(ii) 建立一个根据年龄和并发症调整的最佳RTU模型;(iii) 研究老年头颈癌患者对治疗的耐受性和毒性:根据新南威尔士州癌症登记记录(2010-2014 年)、放射治疗数据(2010-2015 年)和入院患者数据(2008-2015 年),对确诊为头颈部癌症的患者进行回顾性队列研究。我们按年龄组(包括 80 岁以上的患者)计算了实际 RTU,即在确诊后一年内接受至少一个疗程放疗的患者比例。我们还计算了年龄和合并症调整后的最佳 RTU。在治疗耐受性方面,我们计算了每个年龄组的放疗剂量和为期七周的 70 克瑞(Gy)治愈性放疗疗程的完成率。急诊科(ED)就诊人数被用作接受 70 Gy 治疗的患者急性治疗毒性的替代指标:在 5966 名确诊为头颈部癌症的患者中,有 814 人(13.6%)的年龄在 80 岁以上。在所有年龄组中,实际 RTU 均小于最佳 RTU。经年龄和合并症调整后,80 岁以上患者的最佳 RTU 为 52%(95% CI:51%-53%),实际 RTU 为 40%(95% CI:37%-44%)。只有 4.4% 的 80 岁以上患者接受了 70 Gy 的放疗,这些患者 70 Gy 放疗疗程的完成率为 92%。各年龄组的急诊室就诊率相似:结论:在所有年龄组中,80 岁以上患者的实际 RTU 都较低。结论:尽管治愈性放疗的完成率和急性毒性相似,但与较年轻年龄组的实际 RTU 相比,80 岁以上年龄组接受治愈性放疗的患者较少。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical oncology
Clinical oncology 医学-肿瘤学
CiteScore
5.20
自引率
8.80%
发文量
332
审稿时长
40 days
期刊介绍: Clinical Oncology is an International cancer journal covering all aspects of the clinical management of cancer patients, reflecting a multidisciplinary approach to therapy. Papers, editorials and reviews are published on all types of malignant disease embracing, pathology, diagnosis and treatment, including radiotherapy, chemotherapy, surgery, combined modality treatment and palliative care. Research and review papers covering epidemiology, radiobiology, radiation physics, tumour biology, and immunology are also published, together with letters to the editor, case reports and book reviews.
期刊最新文献
PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis. "If You're Talking, I Think You're Muted": Follow-up Analysis of Weekly Peer Review Discussion and Plan Changes After Transitioning From Virtual to In-Person Format. The Current use of Adaptive Strategies for External Beam Radiotherapy in Cervical Cancer: A Systematic Review. The Use of Artificial Intelligence Technologies in Cancer Care. Response Letter to Laurelli et al. Letter to the Editor Regarding Enhancing Telemedicine to Improve Global Radiotherapy Access.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1